These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38745575)

  • 41. Boxed warning inconsistencies between drug information resources and the prescribing information.
    Cheng CM; Fu C; Guglielmo BJ; Auerbach AD
    Am J Health Syst Pharm; 2011 Sep; 68(17):1626-31. PubMed ID: 21856808
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
    Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
    Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Summaries of safety labeling changes approved by FDA-boxed warnings highlights, April-June 2023.
    Am J Health Syst Pharm; 2023 Sep; 80(19):1297. PubMed ID: 37624625
    [No Abstract]   [Full Text] [Related]  

  • 44. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018.
    Fan M; Chan AYL; Yan VKC; Tong X; Lau LKW; Wan EYF; Tam EYT; Ip P; Lum TY; Wong ICK; Li X
    Orphanet J Rare Dis; 2022 Jan; 17(1):3. PubMed ID: 34983612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, July-September 2023.
    Am J Health Syst Pharm; 2024 Jan; 81(2):3-4. PubMed ID: 37993264
    [No Abstract]   [Full Text] [Related]  

  • 46. The Value of the Black Box Warning in Dermatology.
    Winterfield L; Vleugels RA; Park KK
    J Drugs Dermatol; 2015 Jul; 14(7):660-6. PubMed ID: 26151780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Summaries of Safety Labeling Changes Approved By FDA—Boxed Warnings Highlights January-March 2015.
    Rubio T
    Am J Health Syst Pharm; 2015 Jun; 72(11):900, 902, 904. PubMed ID: 25987678
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.
    Bian J; Chen B; Hershman DL; Marks N; Norris L; Schulz R; Bennett CL
    J Clin Oncol; 2017 Jun; 35(17):1945-1951. PubMed ID: 28441110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
    Matlock A; Allan N; Wills B; Kang C; Leikin JB
    Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Summaries of safety labeling changes approved by FDA-boxed warnings highlights January-March 2016.
    Am J Health Syst Pharm; 2016 Jun; 73(11):739-40. PubMed ID: 27208054
    [No Abstract]   [Full Text] [Related]  

  • 51. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, April-June 2018.
    Office of Health and Constituent Affairs, U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2018 Sep; 75(17):e642-e653. PubMed ID: 30139737
    [No Abstract]   [Full Text] [Related]  

  • 52. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
    Downing NS; Shah ND; Aminawung JA; Pease AM; Zeitoun JD; Krumholz HM; Ross JS
    JAMA; 2017 May; 317(18):1854-1863. PubMed ID: 28492899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, July-September 2022.
    Am J Health Syst Pharm; 2022 Dec; 79(24):e157-e160. PubMed ID: 36377403
    [No Abstract]   [Full Text] [Related]  

  • 54. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, July-September 2022.
    Traynor K
    Am J Health Syst Pharm; 2022 Dec; 79(24):2206-2207. PubMed ID: 36342044
    [No Abstract]   [Full Text] [Related]  

  • 55. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, April-June 2022.
    Am J Health Syst Pharm; 2022 Aug; 79(17):1404. PubMed ID: 35904363
    [No Abstract]   [Full Text] [Related]  

  • 56. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March, 2021.
    Am J Health Syst Pharm; 2021 Jun; 78(13):e6-e8. PubMed ID: 34043003
    [No Abstract]   [Full Text] [Related]  

  • 57. Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making.
    Greiwe J; Honsinger R; Hvisdas C; Chu DK; Lang DM; Nicklas R; Apter AJ
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3057-3063. PubMed ID: 36064185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
    Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
    BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New and incremental FDA black box warnings from 2008 to 2015.
    Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
    Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prescribing Antipsychotic Medications to Patients With Dementia: Boxed Warnings and Mitigation of Legal Liability.
    Rose RV; Kass JS
    Continuum (Minneap Minn); 2019 Feb; 25(1):254-259. PubMed ID: 30707196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.